drugset / Trial / NCT05944926

Summary

The OptimizeD study aims to improve outcomes in depression in primary care in India. This study will randomize 1500 patients with moderate to severe depression to either psychotherapy based on behavioral activation called the Healthy Activity Program (HAP) or antidepressant medication (fluoxetine). The study has two primary objectives: 1. Use patient characteristics to generate a precision treatment rule based on baseline information for predicting in advance what works best for whom (and which patients are unlikely to respond to either treatment and should be referred to specialist care). 2. Conduct a cost-effectiveness analysis by comparing relative costs and effectiveness between those who were randomly allocated to their optimal treatment with those who were randomly allocated to a non-optimal treatment based on the precision treatment rule.

Timeline

Start
2024-03-18
Primary completion
2026-04-10
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 20 mg
Subject Fluoxetine Small molecule 40 mg

Indications